Armata Pharmaceuticals Inc (ARMP)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $143.94M
Last updated: Nov 17, 2026 at 11:03 AM ET
Armata Pharmaceuticals Inc (ARMP) Competitors
The companies most similar to Armata Pharmaceuticals are Invivyd (IVVD), Protara Therapeutics (TARA) and Fate Therapeutics (FATE). By market cap, Armata Pharmaceuticals ranks 10th of the 13 companies on this page; Arcturus Therapeutics Holdings (ARCT) is the largest at $240.96M.
Peer Comparison
ARMP's ROIC of -184.6% is below the peer median of -47.9%, and its revenue growth of 173.6% is above the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Armata Pharmaceuticals (ARMP) | $143.94M | N/A | 14.7x | 0.0% | -184.6% | 173.6% | 0.00% |
| Invivyd Inc. (IVVD) | $171.58M | N/A | 2.9x | -183.9% | N/A | 21.2% | 0.00% |
| Protara Therapeutics Inc (TARA) | $155.77M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Fate Therapeutics Inc (FATE) | $155.74M | N/A | 29.7x | 0.0% | -51.3% | 9.2% | 0.00% |
| Arcturus Therapeutics Holdings Inc (ARCT) | $240.96M | N/A | 7.7x | -285.9% | N/A | 6.7% | 0.00% |
| Innate Pharma (IPHA) | $154.15M | N/A | 17.6x | 0.0% | 489.8% | 16.5% | 0.00% |
| Compass Therapeutics Inc. (CMPX) | $139.35M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| MacroGenics Inc (MGNX) | $140.60M | N/A | 1.2x | -36.6% | -108.7% | -64.8% | 0.00% |
| Upstream Bio, Inc. (UPB) | $152.38M | N/A | 41.0x | 0.0% | N/A | -42.2% | 0.00% |
| Atrium Therapeutics, Inc. Common Stock (RNA) | $162.00M | N/A | 3.3x | -180.9% | -44.5% | 24.2% | 0.00% |
| Palisade Bio Inc (PALI) | $201.01M | N/A | 436.8x | 0.0% | N/A | 0.0% | 0.00% |
| Pyxis Oncology Inc (PYXS) | $188.98M | N/A | 11.6x | 0.0% | N/A | 0.0% | 0.00% |
| Anixa Biosciences Inc (ANIX) | $91.08M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $155.76M | N/A | 11.6x | 0.0% | -47.9% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Armata Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Invivyd Inc. (IVVD) | Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery... | IVVD competitors |
| Protara Therapeutics Inc (TARA) | Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment... | TARA competitors |
| Fate Therapeutics Inc (FATE) | Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. | FATE competitors |
| Arcturus Therapeutics Holdings Inc (ARCT) | Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases. | ARCT competitors |
| Innate Pharma (IPHA) | Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France... | |
| Compass Therapeutics Inc. (CMPX) | Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple... | CMPX competitors |
| MacroGenics Inc (MGNX) | MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. | MGNX competitors |
| Upstream Bio, Inc. (UPB) | Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. | UPB competitors |
| Atrium Therapeutics, Inc. Common Stock (RNA) | Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies. | RNA competitors |
| Palisade Bio Inc (PALI) | Leading BioSciences, Inc. develops therapies to improve human health through therapeutic protection of the gastrointestinal mucosal barrier. | PALI competitors |
| Pyxis Oncology Inc (PYXS) | Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb)... | PYXS competitors |
| Anixa Biosciences Inc (ANIX) | Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. | ANIX competitors |
Frequently Asked Questions About ARMP
Who are Armata Pharmaceuticals' main competitors?
The companies most similar to Armata Pharmaceuticals include Invivyd (IVVD), Protara Therapeutics (TARA), Fate Therapeutics (FATE), Arcturus Therapeutics Holdings (ARCT) and Innate Pharma (IPHA), listed from the closest match.
Who is Armata Pharmaceuticals' biggest competitor?
Arcturus Therapeutics Holdings (ARCT) is the largest of the similar companies at $240.96M; Invivyd (IVVD) is the closest match by business profile, size, sector and industry.
How does ARMP stock compare with its competitors?
ARMP's P/S is 14.7x against a peer median of 11.6x; its net margin is 0.0% against a peer median of 0.0%.
Which of Armata Pharmaceuticals' competitors pays a higher dividend?
Armata Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Armata Pharmaceuticals bigger than its competitors?
No. Armata Pharmaceuticals is 10th by market cap among the 13 companies on this page; the largest is Arcturus Therapeutics Holdings (ARCT) at $240.96M.
ARMP pages: Overview, Earnings, Forecast, Financials, Competitors